
Claims

1. A crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide



wherein

- said crystalline form of the compound is characterized by the presence of at least four peaks in the X-ray powder diffractogram at angles of refraction 2θ selected from: 4.3°, 13.1°, 13.5°, 14.8°, 17.2°, 19.5°, 21.1°, 21.6°, 22.6°, and 25.0°;
- said crystalline form of the compound is characterized by the presence of at least four peaks in the X-ray powder diffractogram at angles of refraction 2θ selected from: 4.2°, 13.3°, 16.7°, 16.9°, 18.9°, 20.8°, 22.5°, 23.5°, 25.6°, and 27.2°; or
- said crystalline form of the compound is characterized by the presence of at least four peaks in the X-ray powder diffractogram at angles of refraction 2θ selected from: 3.9°, 11.9°, 15.0°, 15.8°, 17.0°, 19.8°, 22.4°, 23.3°, 23.8°, and 27.8°;

wherein said X-ray powder diffractogram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of +/- 0.1-0.2°.

2. A crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide, wherein

- said crystalline form of the compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 4.3°, 17.2°, and 22.6°;
- said crystalline form of the compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 13.3°, 20.8°, and 22.5; or
- said crystalline form of the compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 3.9°, 15.8°, and 19.8°;

wherein said X-ray powder diffractogram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of +/- 0.1-0.2°.

3. A crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide according to claim 1, wherein

- said crystalline form of the compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 4.3°, 17.2°, 21.1°, 21.6°, and 22.6°;
- said crystalline form of the compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 4.2°, 13.3°, 18.9°, 20.8°, and 22.5°; or
- said crystalline form of the compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 3.9°, 15.8°, 19.8°, 23.8°, and 27.8°;

wherein said X-ray powder diffractogram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of +/- 0.1-0.2°.

4. A crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide according to claim 1, wherein

- said crystalline form of the compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 4.3°, 13.1°, 13.5°, 14.8°, 17.2°, 19.5°, 21.1°, 21.6°, 22.6°, and 25.0°;
- said crystalline form of the compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 4.2°, 13.3°, 16.7°, 16.9°, 18.9°, 20.8°, 22.5°, 23.5°, 25.6°, and 27.2°; or
- said crystalline form of the compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 3.9°, 11.9°, 15.0°, 15.8°, 17.0°, 19.8°, 22.4°, 23.3°, 23.8°, and 27.8°;

wherein said X-ray powder diffractogram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of +/- 0.1-0.2°.

5. A crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide according to claim 1, which essentially shows the X-ray powder diffractogram of:

- the crystalline form depicted in Figure 1;
- the crystalline form depicted in Figure 2; or
- the crystalline form depicted in Figure 3;

wherein said X-ray powder diffractogram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of +/- 0.1-0.2°.

6. The crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide according to any one of claims 1 to 5, for use in the manufacture of a pharmaceutical composition, wherein said pharmaceutical composition comprises as active ingredient the compound {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and at least one therapeutically inert excipient.

7. A pharmaceutical composition comprising as active ingredient a crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide according to any one of claims 1 to 5, and at least one therapeutically inert excipient.

8. The use of a crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide according to any one of claims 1 to 5, in the manufacture of a medicament, wherein said medicament is for the treatment of hypertension, pulmonary hypertension, coronary diseases, cardiac insufficiency, renal and myocardial ischemia, renal failure, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, Raynaud's syndrome, digital ulcers or portal hypertension as well as for the treatment or prevention of atherosclerosis, restenosis after balloon or stent angioplasty, inflammation, stomach and duodenal ulcer, cancer, melanoma, prostate cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, pulmonary fibrosis, gram negative septicemia, shock, sickle cell anemia, glomerulonephritis, renal colic, glaucoma, connective tissue diseases, diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain or hyperlipidemia.

9. The use of a crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide according to any one of claims 1 to 5, in the manufacture of a medicament, wherein said medicament is for the treatment of hypertension; CKD including CKD caused by / associated with hypertension, and/or caused by / associated with diabetes (DKD); acute or chronic renal failure; diabetic nephropathy; glomerulonephritis; or heart failure (HF) including chronic HF.

10. The use of a crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide according to claim 9, wherein said medicament is for the treatment of essential hypertension, resistant hypertension, pulmonary hypertension or pulmonary arterial hypertension.

11. The use of a crystalline form of the compound sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide according to claim 9, wherein said medicament is for the treatment of resistant hypertension.